Low CFB expression is independently associated with poor overall and disease-free survival in patients with lung adenocarcinoma.

ABSTRACT: Complement factor B (CFB) serves a pivotal role in the alternative signaling pathway of the complement system and exerts a key role in the labelling of target particles, resulting from effective clearance of the target. The present study aimed to investigate the association between low expression levels of CFB and the clinical features and survival status of patients with lung adenocarcinoma (LUAD). Patient data were based on RNA-sequencing and clinical data from The Cancer Genome Atlas database. All patients were divided into two groups based on the median expression of CFB. Kaplan-Meier curve and univariate Cox regression analyses were used to investigate the association between CFB and survival status. Gene set enrichment analysis was used to examine the effects of CFB expression on sig

SUBMITTER: He C 

PROVIDER: S-EPMC8100962 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature